Inotek Pharmaceuticals Presentations at ARVO 2009

April 29, 2009

Inotek Pharmaceuticals announced that preclinical data supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented in a poster session at ARVO.

INO-8875 is a highly selective adenosine-1 receptor agonist currently completing a Phase 1/2 trial as a topical agent for the treatment of elevated intraocular pressure (IOP) associated with primary open angle glaucoma and ocular hypertension. The preclinical data suggests that INO-8875 lowers IOP primarily by restoring trabecular meshwork outflow, the most important outflow pathway to maintain IOP in healthy eyes. Additionally, INO-8875 may have a secondary mechanism of action to decrease IOP by reducing aqueous humor production.

Read the full release.




Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below